ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CBIO vs PBYI // EV/EBITDA & P/E VALUATION

Crescent Biopharma Inc. (NASDAQ) VS. Puma Biotechnology Inc (NASDAQ) • 15-METRIC TALLY: CBIO 1 — PBYI 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBIO VS. PBYI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CBIO PBYI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 29.30% -64.30 PBYI /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 13.8x — TIE /valuation <GO>
Free Cash Flow Yield -13.86% 7.67% -21.53 PBYI /fcf-yield <GO>
Operating Margin -60.00% 16.30% -76.30 PBYI /operating-margins <GO>
Net Profit Margin 1.40% 13.60% -12.20 PBYI /net-margins <GO>
Revenue Growth (YoY) — -0.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.36 0.20 +6.16 CBIO /balance-sheet <GO>
Piotroski F-Score Quality 3/9 8/9 -5.00 PBYI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.1 52.9 -6.82 PBYI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 16.3x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $522.6M $544.1M -$21.5M PBYI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CBIO REV PBYI REV CBIO GROSS % PBYI GROSS % CBIO FCF PBYI FCF
FY 2025 $10.8M $228.4M — 74.5% -$72.5M $41.7M
FY 2024 $0 $230.5M — 72.1% -$31.1M $38.9M
FY 2023 $0 $235.6M — — -$34.9M $27.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBIO // BETA —
PBYI // BETA —